Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Stake Reduced by Hsbc Holdings PLC

Hsbc Holdings PLC decreased its holdings in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 3.3% in the 4th quarter, HoldingsChannel.com reports. The firm owned 16,879 shares of the specialty pharmaceutical company’s stock after selling 576 shares during the period. Hsbc Holdings PLC’s holdings in Collegium Pharmaceutical were worth $483,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Nisa Investment Advisors LLC boosted its holdings in Collegium Pharmaceutical by 14.5% during the fourth quarter. Nisa Investment Advisors LLC now owns 2,493 shares of the specialty pharmaceutical company’s stock worth $71,000 after buying an additional 316 shares in the last quarter. AlphaQuest LLC boosted its stake in shares of Collegium Pharmaceutical by 3.0% during the 4th quarter. AlphaQuest LLC now owns 12,780 shares of the specialty pharmaceutical company’s stock worth $366,000 after acquiring an additional 374 shares in the last quarter. Foundry Partners LLC grew its holdings in shares of Collegium Pharmaceutical by 2.4% in the 4th quarter. Foundry Partners LLC now owns 16,162 shares of the specialty pharmaceutical company’s stock worth $463,000 after acquiring an additional 381 shares during the last quarter. Gallacher Capital Management LLC raised its position in shares of Collegium Pharmaceutical by 3.3% during the fourth quarter. Gallacher Capital Management LLC now owns 14,571 shares of the specialty pharmaceutical company’s stock worth $417,000 after purchasing an additional 470 shares during the period. Finally, Caprock Group LLC lifted its holdings in shares of Collegium Pharmaceutical by 6.7% during the fourth quarter. Caprock Group LLC now owns 8,698 shares of the specialty pharmaceutical company’s stock valued at $249,000 after purchasing an additional 543 shares during the last quarter.

Insiders Place Their Bets

In other Collegium Pharmaceutical news, CFO Colleen Tupper sold 10,445 shares of the business’s stock in a transaction that occurred on Tuesday, March 11th. The shares were sold at an average price of $30.01, for a total value of $313,454.45. Following the completion of the sale, the chief financial officer now directly owns 165,246 shares of the company’s stock, valued at $4,959,032.46. The trade was a 5.95 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Shirley R. Kuhlmann sold 40,000 shares of the firm’s stock in a transaction on Tuesday, March 4th. The shares were sold at an average price of $28.08, for a total transaction of $1,123,200.00. Following the transaction, the executive vice president now owns 154,204 shares in the company, valued at $4,330,048.32. This represents a 20.60 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 81,693 shares of company stock valued at $2,334,994 in the last three months. Insiders own 2.51% of the company’s stock.

Analyst Ratings Changes

COLL has been the topic of several recent analyst reports. HC Wainwright restated a “buy” rating and set a $50.00 price objective on shares of Collegium Pharmaceutical in a report on Monday, March 24th. StockNews.com lowered shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a report on Saturday, April 19th. Piper Sandler decreased their price objective on shares of Collegium Pharmaceutical from $37.00 to $36.00 and set a “neutral” rating for the company in a research note on Tuesday, February 4th. Finally, Needham & Company LLC reissued a “buy” rating and set a $46.00 target price on shares of Collegium Pharmaceutical in a research note on Wednesday, April 9th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Collegium Pharmaceutical has an average rating of “Moderate Buy” and a consensus price target of $43.60.

Collegium Pharmaceutical Stock Performance

Shares of COLL opened at $27.03 on Wednesday. The company has a market capitalization of $868.53 million, a PE ratio of 11.65 and a beta of 0.63. The company has a debt-to-equity ratio of 3.43, a quick ratio of 0.88 and a current ratio of 0.97. The company’s 50 day moving average price is $28.15 and its 200 day moving average price is $30.21. Collegium Pharmaceutical, Inc. has a 52 week low of $23.23 and a 52 week high of $42.29.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its quarterly earnings results on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 EPS for the quarter, beating the consensus estimate of $1.54 by $0.09. Collegium Pharmaceutical had a net margin of 14.78% and a return on equity of 104.67%. The business had revenue of $181.95 million for the quarter, compared to analysts’ expectations of $179.68 million. Research analysts expect that Collegium Pharmaceutical, Inc. will post 5.62 EPS for the current fiscal year.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.